19 results about "Immune clearance" patented technology

Provided herein are methods of using modified immune cells (e.g., CAR-NK cells) and CNIs to treat a disease or disorder or reduce immune clearance.

The instant application describes improved methods and compositions for the systemic delivery of therapeutic exosomes to a subject in need thereof. In certain embodiments, the current invention reduces the amount of exosomes delivered to liver, spleen and combinations thereof to allow greater distribution to other areas of the body such as, but not limited to, the brain, pancreas, lung, kidney, muscle. In certain embodiments, the methods involve the injection of one or multiple doses of non-therapeutic exosomes prior to the injection of a suitable therapeutic dose of exosomes with a therapeutic payload. Also included are methods to improve immune clearance of exosomes in subjects by inhibiting phagocytosis.

The present application relates to the application of an oncolytic virus carrying interleukin 10 in the field of colorectal cancer liver metastasis. The present application provides the use of a recombinant oncolytic virus in the preparation of a drug for treating colorectal cancer liver metastasis, wherein the recombinant oncolytic virus expresses interleukin 10. The recombinant oncolytic virus provided in the present application can overcome the immune clearance of the virus and the immunosuppression of the liver metastasis in the treatment of colorectal cancer liver metastasis, thereby improving the treatment effect of colorectal cancer liver metastasis.

This invention discloses a two-dimensional hydrogen germanene nanosheet, its preparation method, and its applications. The two-dimensional hydrogen germanene nanosheet has an ultrathin layered structure, with covalently modified hydrogen atoms on its surface, a lateral dimension of 100–300 nm, and a thickness of 5–10 nm. When activated by a specific wavelength laser, the two-dimensional hydrogen germanene nanosheet can photoexcite and generate singlet oxygen to destroy bacterial biofilms and kill bacteria. Simultaneously, it consumes local oxygen to create a staged hypoxic microenvironment, thereby inhibiting excessive inflammatory responses. After the light exposure ends, as the local oxygen level naturally recovers, it can further enhance the infection clearance function of immune cells, achieving continuous clearance of residual infection. This invention, through staged dynamic regulation of oxygen partial pressure, synergistically integrates direct bactericidal and immune clearance processes, ensuring antibacterial strength while reducing the risk of tissue damage and infection recurrence. It is suitable for the safe and effective treatment of implant-related biofilm infections.

The application discloses a gel preparation preparation method for improving cervical HPV infection and establishing a preventive barrier, relates to the technical field of gel preparation, and aims to solve the technical problems that the existing treatment methods are mostly focused on treating infected patients, and there are obvious deficiencies in the prevention of HPV infection, especially in establishing an effective preventive barrier in uninfected people, including: a crushing mechanism, which is mainly used for crushing raw materials, the crushing mechanism comprises a cabinet body, a cabinet door is arranged on one side of the cabinet body, a crushing barrel is arranged in the cabinet door, and a rotating motor matched with the crushing barrel is arranged on the cabinet door; a reverse osmosis mechanism, which is mainly used for controlling the osmotic pressure of the gel. The application has the advantages of activating local immune cells of the cervix, promoting cytokine secretion, enhancing the immune clearance ability of the body to HPV virus, providing long-acting preventive protection for the cervix, and reducing the risk of HPV infection.

The invention discloses an engineering fibroblast as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the engineering fibroblast provided by the invention, a proinflammatory factor IL-1 is neutralized by secreting IL-1RA, an inflammatory loop mediated by the proinflammatory factor IL-1 is broken, and a tumor immune microenvironment is remodeled, so that inhibition on immune effector cells (such as T cells and NK cells) is indirectly and effectively relieved, and favorable conditions are created for other immunotherapy methods or body autoimmune clearance; the problem that the immunosuppressive tumor microenvironment cannot be regulated and controlled well is solved. Meanwhile, the defects that the half-life period of the recombinant IL-1RA protein is short, frequent administration is needed, the local drug concentration of the focus is difficult to maintain and the like are overcome, stable and high-concentration delivery of the therapeutic protein is realized, and the pharmacokinetic bottleneck of the traditional protein drug is overcome.

The invention discloses a biological system based on metabolic affinity and application of the biological system in preparation of antitumor drugs and detection kits. According to the system, selective metabolic affinity screening is carried out based on living microorganisms through an in-vitro adaptability protocol, and selective recognition of a tumor microenvironment, local generation of a bioactive agent and biological restraint are achieved. The system integrates chemotropism detection of tumor metabolic markers, biologic and adaptive decision based on nutritional gradients, controlled production of biologically active metabolites, and a safety architecture. And the self-amplification treatment effect in proportion to the tumor load is realized through a nutrition chemical trend mechanism. The invention aims to eliminate systemic toxicity of traditional chemotherapy through concentration gradient mediated super localized release, reduce production cost through controlled self-replication in continuous flow biological reaction, and guarantee safety through immune clearance. Affinity can be obtained through a metabolic adaptation experiment, the method is suitable for various tumors through a modular reselection protocol, and a new direction is provided for metastatic cancer treatment.

The application relates to the technical field of antibodies, in particular to an EpCAM-binding nanobody, a chimeric antigen receptor and application thereof. The EpCAM-binding nanobody provided by the application can efficiently and specifically recognize and bind to EpCAM protein, and can be used for diagnosing and treating diseases taking EpCAM molecules as markers. The application further provides a CAR (chimeric antigen receptor) and a CAR-T cell (T cell) binding to EpCAM protein, the CAR-T cell has a good immune clearance effect of targeting EpCAM, can be used for specifically recognizing and killing cells expressing EpCAM, and can be used for improving and treating diseases taking EpCAM molecules as markers, and has a good application prospect in the diagnosis and treatment of tumors.

The present disclosure relates to the treatment of cancer. In particular, the present disclosure provides novel therapeutic antibodies that target MHC class I chain-associated protein A (MICA) in a manner that reduces the ability of tumor cells to escape immune clearance mediated by natural killer cell group 2D (NKG2D) receptors.

This invention relates to compounds, compositions and methods for preventing or treating malaria by modulating immune responses through Killer-specific Secretory Protein 37 (Ksp37). The invention provides for the administration of Ksp37, or stimulation of endogenous Ksp37 production using polar compounds such as DMF or DMSO, to increase Ksp37 levels in a subject to therapeutically effective concentrations. Elevated Ksp37 enhances cytotoxic CD8+ T-cell and NK-cell activity, supports cytokine balance, and improves immune clearance of Plasmodium parasites during both liver and blood stages. These approaches promote targeted immune activation, reduce parasite survival, and improve host protection against malaria infection.

This invention belongs to the field of biomedical technology and discloses a targeted delivery biomimetic nanomedicine and its preparation process. The system includes a polylactic acid-glycolic acid copolymer drug-carrying core, a biomimetic cell membrane coating layer, and a pH-responsive polyethylene glycol-arginine block copolymer embedded therein. The latter is anchored to the outer leaflet by a hexadecyl group, maintaining a weakly negative surface charge at physiological pH to evade immune clearance. In the weakly acidic tumor microenvironment, it triggers arginine guanidine matrix protonation, converting the surface potential to a positive charge and enhancing electrostatic adsorption with tumor cells. The core of this invention lies in constructing a dynamic charge interface with spatiotemporal resolution. This interface achieves sequential activation of immune escape and cell adsorption functions at the system level, rather than a simple superposition. This technical approach not only improves the drug accumulation efficiency at the tumor site but also provides a universal platform for other nanomedical applications requiring microenvironment-responsive surface regulation.

The application discloses an oral immune system with a cascade response characteristic as well as a preparation method and application thereof, and belongs to the technical field of biological medicine and nano-preparation. The oral immune system comprises, from inside to outside, a core layer, an intermediate modification layer, a functional unit and a protective shell. The core layer is a live rumen coccus outer membrane vesicle. The intermediate modification layer is a polydopamine coating layer coated on the surface of the core layer. The functional unit is a cerium nanoscale enzyme covalently connected to the surface of the polydopamine coating layer through a thio-ketal bond connecting arm. The protective shell is made of calcium carbonate. The oral immune system integrates oral delivery barrier breakthrough, inflammation microenvironment responsiveness antioxidant and pathogenic bacteria specific immune clearance in the same platform, can break the vicious cycle of flora imbalance, oxidative stress and barrier damage in cooperation, and reduces the interference on beneficial symbiotic flora.

The invention discloses for the first time pluripotent cells, including hypoimmune pluripotent ABO blood type O Rhesus Factor negative (HIPO−) cells, that evade rejection by the host allogeneic immune system and avoid blood antigen type rejection. The HIPO− cells comprise reduced HLA-I and HLA-II expression, increased CD47 expression, and a universal blood group O Rh− (“O−”) blood type. The universal blood type is achieved by eliminating ABO blood group A and B antigents as well as eliminating Rh factor expression, or by starting with an O− parent cell line. These new, novel HIPO− cells evade host immune rejection because they have an impaired antigen presentation capacity, protection from innate immune clearance, and lack blood group rejection. The cells of the invention also include O− pluripotent stem cells (iPSCO−) and O− embryonic stem cells (ESCO−). The invention further provides universally acceptable “off-the-shelf” pluripotent cells and derivatives thereof for generating or regenerating specific tissues and organs.

The invention discloses a high-throughput gene sequencing data analysis system based on deep learning, and particularly relates to the technical field of bioinformatics, the system firstly performs quality control and unified coordinate mapping on multi-source sequencing reads, and constructs unified tensor representation; fusing external information through a deep feature extraction network to generate a comprehensive feature vector, and calculating a variation comprehensive risk index by using a gradient boosting tree model; then longitudinal variation risk and immune receptor rearrangement sequencing data are integrated, a clone phylogenetic structure is reconstructed, the internal growth rate, the competition coefficient and the immune clearance intensity coefficient of each clone are estimated, and a clone abundance time sequence with consistent time and space is obtained; and finally, constructing a clone evolution feature vector, mapping the clone evolution feature vector into an immune escape risk index through a support vector machine model, realizing sorting and grading of high-risk clone, and retaining a complete chain capable of being traced back to underlying evidence in the whole process.

The invention discloses an OMVs (at) Se bioactive preparation as well as a preparation method and application thereof. According to the preparation, a core-shell structure is formed by coating bacterial outer membrane vesicles with selenium nanoparticles, targeted delivery to lung macrophages is achieved, ferroptosis of the lung macrophages is effectively inhibited, inflammatory response is cooperatively regulated, the immune clearance ability is enhanced, and therefore the efficient immunotherapy effect on bacterial pneumonia is achieved.

The invention relates to the technical field of composite materials, in particular to an MOF-based composite sensitizer as well as a preparation method and application thereof. According to the MOF-based composite sensitizer, Hf-TCPP is adopted as a core layer, hemoglobin and boron phenylalanine are loaded, pH-sensitive ZIF-8 is adopted as a core shell, S-nitroso-N-acetyl-DL-penicillamine is loaded, oxygen deficit is relieved, tumor cell energy metabolism is adjusted, and the BNCT curative effect is synergistically improved; a ZIF-8 shell layer is stable in a normal physiological environment, avoids early leakage of a boron carrier, is rapidly degraded in a tumor microenvironment, realizes precise controlled release of BPA and SNAP, is modified by hydrophilic polymers such as polyethylene glycol to prolong the blood circulation time and reduce immune clearance, and is functionally modified by folic acid. The preparation method disclosed by the invention is mild in reaction condition, integrates multiple functions of boron loading, targeted delivery, hypoxia relief, synergistic sensitization and the like, does not need to be additionally combined with other medicines, and simplifies a clinical treatment process.

The invention relates to a bionic responsive multifunctional nano agent as well as a preparation method and application thereof, and belongs to the field of biological medicines. According to the nano agent, an anti-inflammatory drug, a contrast agent metal ion and dopamine are self-assembled to form a particle core, and an outer layer wraps a cell membrane to serve as a shell layer. The membrane has excellent biocompatibility, can realize long-term circulation in vivo, avoids immune clearance, and selectively targets an inflammatory site. The nano-agent creatively integrates the characteristics of cell membrane targeting, ROS responsiveness, multifunctional treatment, imaging monitoring and the like, not only provides a multi-target collaborative treatment and precise diagnosis strategy for AP, but also opens up a new thought for development of nano-drugs for other inflammation-related diseases.

The invention relates to the technical field of antibodies, in particular to a nano antibody combined with EpCAM, a chimeric antigen receptor and application of the nano antibody and the chimeric antigen receptor. The nano antibody combined with EpCAM provided by the invention can efficiently and specifically recognize and combine with EpCAM protein, and can be used for diagnosing and treating diseases taking EpCAM molecules as markers. The invention also provides a CAR and a CAR-T cell which are combined with the EpCAM protein, and the CAR-T cell has a good immune clearance effect of targeting the EpCAM, can be used for specifically identifying and killing cells expressing the EpCAM, is used for improving and treating diseases taking EpCAM molecules as markers, and has a relatively good application prospect in diagnosis and treatment of tumors.

Provided herein are methods for treating a disease or disorder, or for reducing immune clearance in a human subject using modified immune cells and a calcineurin inhibitor. The human subject does not undergo lymphodepletion using one or more lymphodepleting agents or radiation therapy.